2016
STJ Advisors advised MorphoSys AG, the German biotechnology company involved in the development of research and antibodies, on their capital increase via an accelerated bookbuild offering, raising proceeds of EUR 115 million.
2016
STJ Advisors advised MorphoSys AG, the German biotechnology company involved in the development of research and antibodies, on their capital increase via an accelerated bookbuild offering, raising proceeds of EUR 115 million.
